Jacobs Solutions delivered its clearest positive surprise in several quarters this week. Q2 adjusted EPS came in at $1.75, beating the $1.63 consensus estimate. Sales of $3.70 billion also topped expectations by a wide margin. The company then raised its full-year adjusted EPS guidance to a range of $7.10–$7.35, above the prior $6.95–$7.30 band and ahead of the $7.16 estimate. The result sent the stock up nearly 8% over the week to close at $136.55.
The analyst reaction following the print was divided — confident enough to keep positive ratings intact, but not uniformly bullish on where the stock goes next. RBC Capital raised its price target to $169 while maintaining Outperform, seeing the upside as intact after the beat. KeyBank moved in the opposite direction, trimming its target to $150 from $154 despite holding its Overweight rating — a signal that the improved guidance is already being weighed against near-term execution risk. Goldman Sachs, which initiated at Buy in late November with a $158 target, reiterated its positive view. The consensus price target of roughly $159 implies around 14% upside from current levels, though the overall rating remains a Hold, with six analysts neutral and four leaning positive. For bulls, the Q2 beat and raised guide represent a genuine inflection. Bears point to the adjusted operating profit margin slipping 9 basis points to 12.7% last quarter and a lower EBITDA forecast for fiscal 2026 that may cap valuation expansion.
Short positioning tells a calm but subtly shifting story. Short interest in Jacobs sits at 3.8% of free float — not extreme, but up roughly 23% over the past month in share terms. Most of that build came in early April, when estimated short shares jumped from around 3.6 million to above 4.3 million in just a few sessions, and then stabilised. The borrow market remains very loose: cost to borrow is running at just 0.33% annualised, and has actually fallen about 28% over the past week even as short interest has ticked higher. Availability is wide, consistent with a stock where bears face no friction in expressing their view. The ORTEX short score of 39.7 — well below the midpoint — places J firmly in the uncrowded camp. Days to cover is 3.2, and the short score percentile rank for the past year is in the 36th percentile. Nothing in the lending market points to meaningful short-side pressure.
Options sentiment is also relaxed. The put/call ratio is 0.40, almost exactly in line with its 20-day average of 0.397, and the z-score is effectively flat at zero. There was a brief spike in defensive positioning in late April — the PCR briefly touched 0.50 on April 20 — but it reverted well ahead of earnings. Into the print, options traders were neither hedging heavily nor positioned aggressively for a breakout. At current RSI-14 of 66, the stock is neither overbought nor oversold.
Institutional ownership is concentrated but stable. Vanguard holds 11.6% and added over 1.36 million shares in the most recent reported quarter. BlackRock owns 8.2% and added 490,000 shares. Both the index-weight buyers and active managers appear comfortable with the position. Insider activity has been quiet since March; a routine sell by a divisional president at $134 per share was the last material transaction. The 90-day net insider position is a modest net sell of 1,440 shares — essentially noise. The dividend history in the snapshot is stale, with no recent payments recorded, so the 1.05% forward yield figure should be treated as approximate.
EPS momentum ranks in the 90th percentile on a forward year-over-year basis — the guide upgrade this week reinforces that trajectory. The next event listed is Q2 results themselves (now past), with no confirmed next earnings date in the calendar. Worth watching is whether the revised guidance translates into further analyst target increases over the coming weeks, and how the stock absorbs the gap between its current $136.55 price and the highest analyst target of $180 (Citigroup, from November 2025 — now six months old and potentially stale relative to more recent targets). The closer-in question is whether the margin compression story that bears have cited starts to reverse, or whether Q3 guidance brings a sharper debate between the RBC bulls and the more cautious mid-$150s camp.
See the live data behind this article on ORTEX.
Open J on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
